Omega Therapeutics Inc

Omega Therapeutics — Investor Presentation (November 2024)

29 slides from Omega Therapeutics's investor presentation, Nov 14, 2024

  1. Slide 1: Harnessing the Power of Epigenomic Controllers

    Slide 1: Harnessing the Power of Epigenomic Controllers

    OMEGA THERAPEUTICS Harnessing the Power of Epigenomic Controllers Pioneering a New Class of Programmable Epigenomic Medicines November 2024

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-look

  3. Slide 3: Omega is Pioneering a New Class of Programmable Epigenomic Medicines

    Slide 3: Omega is Pioneering a New Class of Programmable Epigenomic Medicines

    Omega is Pioneering the Development of a New Class of Programmable Epigenomic Medicines Leader in • Differentiated platform capable of durable gene upregulation, downregulation, and multiplexing; May enable more potent, durable, and safer therapeutics vs. existing modalities Epigenomic • Pre-transcr

  4. Slide 4: Omega's Diverse Capabilities and Expertise Provide Foundation for Value Creation

    Slide 4: Omega's Diverse Capabilities and Expertise Provide Foundation for Value Creation

    Omega’s Diverse Capabilities and Expertise Provide Foundation for Value Creation A Clinically-Proven Platform with Broad Applicability to Nearly Any Gene Robust R&D Proprietary Screened 100 targets Clinical Value-focused Extensive engine for database of 1M unique validated proof-of- pipeline driven

  5. Slide 5: Precision Epigenomic Control is a Significant Technological Advance

    Slide 5: Precision Epigenomic Control is a Significant Technological Advance

    Precision Epigenomic Control is a Significant Technological Advance Access to any target, independent of structure, chemistry or location; addres ses undruggable/ inaccessible targets Pre-transcriptional approach Uncouples PK and PD for potential safety benefit addresses limitations of other modalit

  6. Slide 6: Phase 1 Trial of OTX-2002 Establishes Clinical Proof-of-Mechanism

    Slide 6: Phase 1 Trial of OTX-2002 Establishes Clinical Proof-of-Mechanism

    Data from Completed Phase 1 First-in-Human Trial of OTX-2002 Establish Clinical Proof-of-Mechanism of Omega’s Epigenomic Controller Platform Clinical validation of epigenomic controllers as a potential new class of medicines In Phase 1 trial of late-stage HCC patients, OTX-2002 demonstrated: Predict

  7. Slide 7: Pipeline Focused on Significant Opportunities with Clear Paths to Value Inflection

    Slide 7: Pipeline Focused on Significant Opportunities with Clear Paths to Value Inflection

    Pipeline Focused on Significant Opportunities with Clear Paths to Value Inflection Data-Driven Resource Allocation to Drive Program Advancement Decisions Selection Framework Clear OMEGA biology differentiation Delivery & Clinical technical development feasibility pathway Regulatory Market considerat

  8. Slide 8: Advancing a Focused Pipeline of High-Value Programs

    Slide 8: Advancing a Focused Pipeline of High-Value Programs

    With Clinical Proof-of-Platform Established, Omega is Advancing a Focused Pipeline of High-Value Programs TARGET INDICATION DISCOVERY LEAD OPTIMIZATION IND-ENABLING PARTNER GENE(S) Regenerative Medicine HNF4A Fibrosis regeneration / Liver Metabolic Undisclosed Obesity FGF21 Multi Opportunities -Indi

  9. Slide 9: OMEGA Platform Overview

    Slide 9: OMEGA Platform Overview

    OMEGA Platform Overview OMEGA THERAPEUTICS

  10. Slide 10: Insulated Genomic Domains Are Nature's Control System to Regulate Gene Expression

    Slide 10: Insulated Genomic Domains Are Nature's Control System to Regulate Gene Expression

    Insulated Genomic Domains Are Nature’s Control System to Regulate Gene Expression Nature organizes genes in evolutionarily conserved 3D loops of chromatin called Insulated Genomic Domains (IGDs) IGDs are the fundamental IGD structural E.g., Lung tissue Lung cell and functional units for gene control

  11. Slide 11: OMEGA Platform Engineers Programmable Epigenomic Therapeutics

    Slide 11: OMEGA Platform Engineers Programmable Epigenomic Therapeutics

    OMEGA Platform Engineers Programmable Epigenomic Therapeutics Gene BIOLOGY TECHNOLOGY New Drug Targets Epigenomic Controllers Epigenomic effector Epigenomic • Insulated genomic Controller • mRNA expresses a fusion domains (IGDs): Linker protein consisting of: DNA-binding Contain genes and their doma

  12. Slide 12: Pre-transcriptional control of gene expression

    Slide 12: Pre-transcriptional control of gene expression

    Pre-transcriptional control of gene expression leveraging nature’s control system 11 Unique Epigenomic Control at Pre-transcriptional Level Precise binding to On-target binding with robust change in epigenetic state Exquisite ~21 base pair sequence(s) of single gene in IGD on chromosome 8 Specificit

  13. Slide 13: Durable Upregulation of Multiple Gene Targets

    Slide 13: Durable Upregulation of Multiple Gene Targets

    Durable Upregulation of Multiple Gene Targets (1) Inactive Gene (2) Expressed Gene (3) Poised Gene Upregulation achieved across diverse Control Control Control genes, including: 2 1 1 1 2 3 EC 3 2 4 4 3 1. Genes that are inactive in a cell type of interest 5 6 5 4 1 10 100 1000 10000 100000 5 7 8 6

  14. Slide 14: Proof-of-Concept Demonstrated Across Diverse Set of Disease Areas

    Slide 14: Proof-of-Concept Demonstrated Across Diverse Set of Disease Areas

    Proof-of-Concept Demonstrated Across Diverse Set of Disease Areas Oncology (MYC HCC) Liver Regeneration (HNF4a) Statistically significant inhibition of HCC tumor growth Significant improvement in liver histology in murine model of fibrosis in vivo through direct targeting of c-MYC 1000 Negative Cont

  15. Slide 15: Prioritized Programs

    Slide 15: Prioritized Programs

    Prioritized Programs OMEGA THE RAPEUTICS

  16. Slide 16: Obesity Thermogenesis Research Collaboration with Novo Nordisk

    Slide 16: Obesity Thermogenesis Research Collaboration with Novo Nordisk

    Obesity Thermogenesis Research Collaboration with Novo Nordisk Opportunity For Orthogonal and Transformative Innovation In Obesity • Collabor ation validates broad applicabi lity • Trans-differentiation of human adipose tissue: of the OMEGA platform Transitioning the epigenetic state of white to met

  17. Slide 17: HNF4A: Potential Opportunity in Fibrotic Liver Diseases

    Slide 17: HNF4A: Potential Opportunity in Fibrotic Liver Diseases

    HNF4a HNF4A: Potential Opportunity in Fibrotic Liver Diseases EC Significantly Upregulated Gene Expression and Reduced Key Fibrosis Measures In Vivo • HNF4α is a critical transcriptional …HNF4α Induction Conferred regulator of hepatocyte HNF4α Expression Protection in DDC Fibrosis Model different

  18. Slide 18: HNF4A-EC Selectively and Durably Upregulated P1 Isoform

    Slide 18: HNF4A-EC Selectively and Durably Upregulated P1 Isoform

    HNF4a HNF4A-EC Selectively and Durably Upregulated P1 Isoform and Restored Dysregulated Expression Caused by TGFβ Signaling In Vitro HNF4A-EC Treatment Increased HNF4α-P1 HNF4A-EC Treatment Rescued TGFB1-induced Isoform Expression for 35 Days in HNF4 P1 Downregulation in Primary Human Hepatocytes

  19. Slide 19: HNF4A-EC Robustly Upregulated HNF4α Expression Across Species

    Slide 19: HNF4A-EC Robustly Upregulated HNF4α Expression Across Species

    HNF4a HNF4A-EC Robustly Upregulated HNF4α Expression Across Species Increased HNF4α Expression in Healthy Liver Tissues (Over and Above Normal Expression) Species Mouse Nonhuman primate FRG Mouse Liver Cells Mouse (48h) Nonhuman primate (24h) Human (24h) 500 250 150 * (%) 400 200 * (%) (%) 100 exp

  20. Slide 20: FGF21: Potential for Multi-Indication Metabolic Opportunities

    Slide 20: FGF21: Potential for Multi-Indication Metabolic Opportunities

    FGF21 FGF21: Potential for Multi-Indication Metabolic Opportunities Plan for Rapid Proof-of-Concept Readout of Upregulation Capabilities In Vitro Upregulation Observed Across Multiple Epigenomic Effectors • FGF21 is a hepatocyte-derived hormone involved in energy homeostasis, and Control Effector 1

  21. Slide 21: Strategic Partnerships Core to Omega's Corporate Strategy

    Slide 21: Strategic Partnerships Core to Omega's Corporate Strategy

    Strategic Partnerships Core to Omega’s Corporate Strategy Partnering Strategy Support development Extend pipeline into Advance further of prioritized programs additional high-value development of OTX-2002 or targets and tissues other assets Actively engaged in dialogue with potential partners to bri

  22. Slide 22: Pioneering a New Class of Programmable Epigenomic Medicines

    Slide 22: Pioneering a New Class of Programmable Epigenomic Medicines

    Pioneering a New Class of Programmable Epigenomic Medicines Pre-transcriptional gene modulation enables durable gene upregulation, downregulation, and multiplexing Clinical proof-of-mechanism validates epigenomic controllers and de-risks OMEGA platform Advancing pipeline of select high-value program

  23. Slide 23: OMEGA THE RAPEUTICS

    Slide 23: OMEGA THE RAPEUTICS

    OMEGA THE RAPEUTICS 23

  24. Slide 24: Building Value Through Differentiated Capabilities: Additional Sample Data

    Slide 24: Building Value Through Differentiated Capabilities: Additional Sample Data

    Building Value Through Differentiated Capabilities Additional Sample Data OMEGA THE RAPEUTICS

  25. Slide 25: HBB: Durable Upregulation Observed for ~2 Months

    Slide 25: HBB: Durable Upregulation Observed for ~2 Months

    Upregulation HBB: Durable Upregulation Observed for ~2 Months With Single Administration; No DNA Sequence Changes as Associated with Transgenic Approaches In Vitro Hemoglobin Activation Change in Epigenetic State Untreated Untreated Expression EC EC HbB Relative ****p 0.0001 25

  26. Slide 26: PCSK9: Durable Downregulation Maintained Through 6 Months

    Slide 26: PCSK9: Durable Downregulation Maintained Through 6 Months

    Downregulation PCSK9: Durable Downregulation Maintained Through 6 Months Following Single Administration; Enables Less Frequent Dosing In Vivo PCSK9 Downregulation Change in Epigenetic State 4x105 Untreated 40 Untreated EC EC (pg/mL) 3x105 30 2x105 Methylation 20 PCSK9 **** **** Serum 1x105 Percent

  27. Slide 27: Multigenic Targeting of CXCL1-8 Downregulated Chemokine mRNA Expression

    Slide 27: Multigenic Targeting of CXCL1-8 Downregulated Chemokine mRNA Expression

    Multiplexing Multigenic Targeting of CXCL1-8 Downregulated Chemokine mRNA Expression and Reduced Neutrophil Migration in Donor Lung Fibroblasts In Vitro Coordinated Downregulation of mRNA Expression Significant Decrease in Neutrophil Migration Donor 1 Donor 2 Donor 3 150 Control 125 125 125 level CX

  28. Slide 28: CXCL9-11-Targeting EC Reduced mRNA Expression and Protein Levels

    Slide 28: CXCL9-11-Targeting EC Reduced mRNA Expression and Protein Levels

    Multiplexing CXCL 9-11-Targeting EC Reduced mRNA Expression and Protein Levels in IFNG-Stimulated Primary Human Hepatocytes CXCL9 CXCL10 CXCL11 1.5 1.5 1.5 T-cell migration Treated Treated Treated reduced by 75%—IFNG IFNG—IFNG -vs 1.0 vs 1.0vs 1.0 100 GAPDH) GAPDH) GAPDH) / / / mRNA Change 0.5 * Cha

  29. Slide 29: Omega Has Extensive Internal Delivery Capabilities

    Slide 29: Omega Has Extensive Internal Delivery Capabilities

    Delivery Omega Has Extensive Internal Delivery Capabilities Additional Proprietary LNPs Targeting CNS, Joints, Skin and Adipose in Development Lung (Systemic & Inhaled) CNS Pancreas Intratracheal Intrathecal IP injection Systemic Conducting Airway Reporter/Basal/Club Adipose tissue Joint Dermis Deli

Source: SEC EDGAR · 8-K filed Nov 14, 2024

More decks from Omega Therapeutics Inc